A Prospective, Multicentre, Open-Label Single-Arm Exploratory Study to Evaluate Efficacy and Safety of Saroglitazar on Hypertriglyceridemia in HIV Associated Lipodystrophy.

PloS One
Alka DeshpandeRajendrakumar H Jani

Abstract

This study was designed to explore the efficacy and safety of saroglitazar 4 mg on hypertriglyceridemia in patients with HIV associated lipodystrophy. During this 12-week prospective, multi-centric, open-label, single arm exploratory study, 50 patients were enrolled to receive saroglitazar 4 mg orally once daily in the morning before breakfast. The primary efficacy endpoint was the percent change in triglyceride (TG) levels from baseline to Week 6 and Week 12. The secondary efficacy endpoints were assessment of low-density-lipoprotein (LDL), very-low-density-lipoprotein (VLDL), high-density-lipoprotein (HDL), non-HDL cholesterol, total cholesterol, apo-lipoprotein (Apo) A1, Apo B, and C-peptide and fasting insulin for HOMA beta and HOMA IR. Safety assessment was performed during the study. Saroglitazar 4 mg significantly decreased the serum TG levels from baseline at Week 6 (percent change: -40.98; 95% CI: -50.82, -31.15) and Week 12 (percent change -45.11; 95% CI: -52.37, -37.86). Reduction in VLDL cholesterol (percent change: -46.33; 95% CI: -52.89, -39.76) and total cholesterol (percent change: 7.37; 95% CI: 1.96, 12.78) was observed at week 12 from baseline. Saroglitazar increased HDL cholesterol (percent change: 34.56, 95%...Continue Reading

References

Mar 10, 2001·Journal of Acquired Immune Deficiency Syndromes : JAIDS·M SchmitzT Demant
May 1, 2002·The Brazilian Journal of Infectious Diseases : an Official Publication of the Brazilian Society of Infectious Diseases·B CaramelliD Uip
Oct 23, 2002·Journal of General Internal Medicine·Michael L Green
Oct 24, 2002·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Rosario PalaciosPedro González-Santos
Jan 25, 2003·The Pediatric Infectious Disease Journal·Ethan G Leonard, Grace A McComsey
May 15, 2003·American Journal of Physiology. Endocrinology and Metabolism·D N ReedsS Klein
May 14, 2004·HIV Medicine·F BonnetUNKNOWN Groupe d'Epidémiologie Clinique du SIDA en Aquitaine (GECSA)
May 29, 2004·Current Opinion in Lipidology·Ashok BalasubramanyamHenry J Pownall
Jun 18, 2004·The American Journal of the Medical Sciences·Archana RaoMario Maldonado
Sep 10, 2004·The New England Journal of Medicine·Hannele Yki-Järvinen
Jun 7, 2011·The Open Cardiovascular Medicine Journal·Eoin R Feeney, Patrick W G Mallon
Feb 2, 2013·Journal of the American College of Cardiology·Franck BoccaraAriel Cohen

❮ Previous
Next ❯

Citations

Mar 21, 2017·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Cristina MaccalliniRosa Amoroso

❮ Previous
Next ❯

Software Mentioned

SAS

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.